Cardiac Marker Testing Market

Cardiac Marker Testing Market by Product (Reagent, Instrument), Component (Troponin I & T, CK-MB, Myoglobin, BNP, hs-CRP), Disease (Myocardial Infarction, Congestive Heart Failure, Atheresclerosis), Enduser (Lab, PoC, Academia) - Global Forecast to 2027

Report Code: MD 4673 Oct, 2022, by marketsandmarkets.com

[210 Pages Report] The global cardiac marker testing market is projected to reach USD 7.7 billion by 2027 from USD 5.0 billion in 2022, at a CAGR of 8.7% during the forecast period.

The major factors such as rising geriatric population globally and the subsequent increase in chronic heart conditions; the rising prevalence of cardiovascular diseases worldwide; and increasing research & funding initiatives from public/private organizations to discover novel cardiac biomarkers are anticipated to drive the growth of the market.

However, technical challenges associated with sampling collection and storage, regulatory issues, and limited reimbursements are expected to restrain the market growth during the forecast period.

Attractive opportunities cardiac marker testing Market

Cardiac Marker Testing Market

To know about the assumptions considered for the study, Request for Free Sample Report

Cardiac marker testing Market Dynamics

Driver: Growing incidence of cardiovascular diseases

Cardiac biomarkers help in the early detection and diagnosis of various cardiovascular diseases, such as myocardial infarction, acute coronary syndrome, heart attack, and heart failure. According to the World Health Organization (WHO), approximately 32.4 million myocardial infarctions or strokes are reported globally annually. In addition, acute coronary syndrome (ACS), a common complication of coronary heart disease, is associated with more than 2.5 million hospitalizations worldwide. Thus, the rising incidence of cardiovascular diseases is anticipated to increase the demand for early diagnosis, further accelerating the adoption of cardiac biomarker tests.

Restraint: Technical problems related to sample collection and storage

Cardiac biomarkers are used in epidemiology study to carry out investigation of different stages of diseases in humans. This process demand a careful handling and storage of precious biological samples to obtain a large amount of information from a limited samples.

A stringent quality control is needed for these samples to provide right condition of storage to avoid the loss of data. Cardiac biomarker studies using archived specimens is dependent on the integrity of specimens and way in which they are collected, processed, and stored. The technical issues in both sample collection and storage are likely to hamper the growth of the overall cardiac biomarkers market, especially the laboratory-based testing segment.

Opportunity: Emerging markets offer high-growth opportunities

Emerging markets such as India and China offer significant growth opportunities for cardiac diagnostics due to the growing patient population due to the increasing burden of cardiovascular diseases in these countries. According to the Indian Heart Association (IHA) 2019, India accounted for 60% of the global heart disease burden, and around 50% of all heart attacks in Indian men occur under the age of 50 years. Similarly, the burden of cardiovascular disease (CVD) has rapidly increased in China owing to the increased risk d cardiovascular disease factors such as high blood cholesterol, obesity, and diabetes mellitus. The increasing burden of cardiovascular diseases in emerging countries will drive the demand for early disease diagnostic, accelerating the adoption of cardiac marker testing products.

By product, the reagents and kits segment is expected to grow at the highest CAGR during the forecast period

The growth of the cardiac marker testing reagents & kits market is attributed to the increasing number of cardiac biomarker tests performed owing to the high burden of cardiovascular diseases (CVD) and rising geriatric patient population worldwide. This has accelerated the demand for rapid diagnosis of CVD, resulting in the adoption of cardiac biomarker rapid test kits. Moreover, the introduction of new cardiac biomarker test kit by players is anticipated to support the growth of the segment.

Troponin I and T is the largest biomarker type segment of the cardiac marker testing market

Cardiac troponin are preferred biomarker for the diagnosis of acute myocardial infarction ( AMI) owing to its higher sensitivity and specificity. Several high-sensitivity troponin assays have been launched in the market in recent times. These high-sensitivity troponin assays can detect the protein quickly and at much lower levels than standard troponin tests. Troponin biomarker are also useful in detecting the risk of future heart events, such as heart attacks, in people with no symptoms. All these factors are anticipated to fuel the growth of the segment in coming years.

The Asia Pacific market is expected to grow at the highest CAGR during the forecast period.

The cardiac marker testing market is segmented into four major regions, namely, North America, Europe, the Asia Pacific, Latin America, and Middle East & Africa. In 2021, North America commanded the largest share of the global diagnostic imaging service market. However, the Asia Pacific market is estimated to grow at the highest CAGR during the forecast period primarily due by the increasing incidence of cardiovascular disease (CVD), increasing testing procedures, improving healthcare infrastructure and rising adoption fo of advanced immunoassay technology among clinical laboratories. Moreover, growing number of local manufacturers offering cardiac marker testing and increasing number of diagnostic laboratories in the region are expected to provide boost the growth of the market in the region

Cardiac Marker Testing Market by Region

To know about the assumptions considered for the study, download the pdf brochure

Key Market Players

F. Hoffmann-La Roche AG (Switzerland), Abbott Laboratories (US), Danaher Corporation (US), Siemens Healthineers AG (Germany), PerkinElmer, Inc. (US), bioMérieux SA (France), Becton, Dickinson and Company (US), Bio-Rad Laboratories, Inc. (US), Thermo Fisher Scientific Inc. (US), DiaSorin (Italy), and Tosoh Corporation (Japan), LSI Medience Corporation (Japan), Quidel Corporation (US), Randox Laboratories (UK), Guangzhou Wondfo Biotech Co., Ltd. (China), Boditech Med Inc. (South Korea), Tulip Diagnostics (P) Ltd (India), BTNX Inc. (Canada), Response Biomedical (Canada), Alfa Scientific Designs, Inc. (US), CTK Biotech, Inc. (US), Creative Diagnostics (US), LifeSign LLC. (US), CardioGenics Holdings Inc (Canada), and Atlas Medical GmbH (Germany).

F. Hoffmann-La Roche: F. Hoffmann-La Roche is one of the key players in the global cardiac marker testing market. The company is a well-established player in the diagnostics segment, and it has a large customer base in diagnostic products, including cardiac marker testing kits. The company focuses on inorganic growth strategies such as agreements and acquisitions to remain competitive in the market. These strategies enable it to expand its point-of-care testing portfolio. Roche Diagnostics strongly invests in R&D activities to improve its existing product portfolio, as it has a strong pipeline of products for the growing market.

Siemens Healthineers AG Due to its robust product portfolio in diagnostic segment, Siemens Healthineers AG is among the leading players in the cardiac marker testing market. The company has a broad range of testing systems for various segments, including hematology, molecular, urinalysis, cardiac, and blood gas testing. The company is engaged in developing and manufacturing new products in the cardiac marker testing market. The company commercializes its products to healthcare providers in more than 180 countries. The distribution of its R&D workforce across international sites has enabled the firm to strengthen its foothold in the market.

Get online access to the report on the World's First Market Intelligence Cloud

  • Easy to Download Historical Data & Forecast Numbers
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
Request Sample

Scope of the Report

Report Metric

Details

Market Size Available for Years

2020–2027

Base Year Considered

2021

Forecast Period

2022–2027

Forecast Units

Value (USD)

Segments Covered

Product, Biomarker Type, Disease, End User, and Region

Geographies Covered

North America (US & Canada), Europe (Germany, UK, France, Italy, Spain, and RoE), APAC (Japan, China, India, Australia, South Korea, and the RoAPAC), LATAM (Brazil, Mexico, and RoLATAM), and MEA

Companies Covered

F. Hoffmann-La Roche AG (Switzerland), Abbott Laboratories (US), Danaher Corporation (US), Siemens Healthineers AG (Germany), PerkinElmer, Inc. (US), bioMérieux SA (France), Becton, Dickinson and Company (US), Bio-Rad Laboratories, Inc. (US), Thermo Fisher Scientific Inc. (US), DiaSorin (Italy), and Tosoh Corporation (Japan), LSI Medience Corporation (Japan), Quidel Corporation (US), Randox Laboratories (UK), Guangzhou Wondfo Biotech Co., among others

This research report categorizes the cardiac marker testing market based on product, biomarker type, disease, end user, and region

By Product

  • Reagents and Kits
  • Instruments
    • Chemiluminescence
    • Immunofluorescence
    • ELISA
    • Immunochromatography

By Biomarker Type

  • Troponin I and T
  • Creatine kinase-MB(CK-MB)
  • Natriuretic peptide (Bnp Or Nt-Probnp)
  • Myoglobin
  • High-sensitivity C-reactive protein(hs-CRP)
  • Other Cardiac Biomarkers

By Disease

  • Myocardial Infarction
  • Congestive Heart Failure
  • Acute Coronary Syndrome
  • Atherosclerosis
  • Ischemia

By End User

  • Laboratory Testing Facilities
    • Hospital Labs
    • Reference Labs
    • Contract Testing Labs
  • Point-Of-Care Testing Facilities
  • Academic Institutions

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • RoE
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Australia
    • RoAPAC
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa

Recent Developments

  • In 2022, Tosoh Corporation announced the launch of the ST AIA-PACK BNP cardiac biomarker for the early diagnosis of heart failure.
  • In 2021, Siemens Healthineers AG entered a strategic partnership with Biognosys AG to accelerate diagnostic protein biomarkers discovery and assay development.
  • In 2019, Abbott Laboratories received FDA approval for the ARCHITECT STAT High Sensitivity Troponin-I blood test used in the diagnosis of myocardial infarction

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 28)
    1.1 STUDY OBJECTIVES
    1.2 MARKET DEFINITION
    1.3 STUDY SCOPE
           1.3.1 MARKETS COVERED
           1.3.2 GEOGRAPHIC SCOPE
           1.3.3 INCLUSIONS & EXCLUSIONS
           1.3.4 YEARS CONSIDERED
    1.4 CURRENCY CONSIDERED
    1.5 LIMITATIONS
    1.6 MARKET STAKEHOLDERS
    1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 32)
    2.1 RESEARCH DATA
          FIGURE 1 RESEARCH DESIGN
           2.1.1 SECONDARY RESEARCH
           2.1.2 PRIMARY RESEARCH
                    2.1.2.1 Key data from primary sources
                                FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS:
                                FIGURE 3 CARDIAC MARKER TESTING MARKET: BREAKDOWN OF PRIMARIES
    2.2 MARKET SIZE ESTIMATION
          FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
           2.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION
           2.2.2 MARKET ESTIMATION BASED ON END USERS
                    FIGURE 5 CARDIAC MARKER TESTING MARKET: MARKET SIZE ESTIMATION
           2.2.3 PRIMARY RESEARCH VALIDATION
    2.3 DATA TRIANGULATION
          FIGURE 6 DATA TRIANGULATION METHODOLOGY
    2.4 RESEARCH ASSUMPTIONS AND LIMITATIONS
           2.4.1 RESEARCH ASSUMPTIONS
           2.4.2 RESEARCH LIMITATIONS

3 EXECUTIVE SUMMARY (Page No. - 40)
    FIGURE 7 CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2022 VS. 2027 (USD MILLION)
    FIGURE 8 CARDIAC MARKER TESTING MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
    FIGURE 9 GEOGRAPHICAL SNAPSHOT OF CARDIAC MARKER TESTING MARKET

4 PREMIUM INSIGHTS (Page No. - 43)
    4.1 CARDIAC MARKER TESTING MARKET OVERVIEW
          FIGURE 10 RISING INCIDENCE OF CARDIOVASCULAR DISEASES AND ONGOING CLINICAL TRIALS FOR NOVEL BIOMARKERS TO DRIVE MARKET
    4.2 CARDIAC MARKER TESTING MARKET SHARE, BY PRODUCT, 2022 VS. 2027
          FIGURE 11 REAGENTS & KITS TO CONTINUE TO DOMINATE MARKET DURING FORECAST PERIOD
    4.3 EUROPE: CARDIAC MARKER TESTING MARKET, BY END USER AND REGION
          FIGURE 12 LABORATORY TESTING FACILITIES SEGMENT ACCOUNTED FOR LARGEST SHARE IN 2021
    4.4 CARDIAC MARKER TESTING MARKET: GEOGRAPHICAL SNAPSHOT
          FIGURE 13 CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 45)
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS
          FIGURE 14 CARDIAC MARKER TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Rising incidence of cardiovascular diseases
                    5.2.1.2 Increasing geriatric population and subsequent rise in heart conditions worldwide
                    5.2.1.3 Growing research & funding initiatives from public & private organizations
                    5.2.1.4 Rising clinical studies for identification of novel cardiac biomarkers
           5.2.2 RESTRAINTS
                    5.2.2.1 Technical issues related to sample collection & storage
                    5.2.2.2 Unfavorable regulatory processes and limited reimbursement structure
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Point-of-care testing with cardiac biomarkers
                    5.2.3.2 Ongoing research on novel cardiac biomarkers for cardiovascular diseases
                    5.2.3.3 Emerging markets offer high-growth opportunities
           5.2.4 CHALLENGES
                    5.2.4.1 Challenges associated with biomarker assay validation
    5.3 REGULATORY SCENARIO
          TABLE 1 KEY REGULATORY BODIES & GOVERNMENT AGENCIES
           5.3.1 KEY REGULATORY GUIDELINES
                    5.3.1.1 US
                                TABLE 2 US: CLASSIFICATION OF IN VITRO DIAGNOSTIC DEVICES
                                FIGURE 15 US: REGULATORY PROCESS FOR IVD DEVICES
                    5.3.1.2 Canada
                                FIGURE 16 CANADA: REGULATORY PROCESS FOR IVD DEVICES IN CANADA
                    5.3.1.3 Europe
                                TABLE 3 EUROPE: CLASSIFICATION OF IVD DEVICES
                                FIGURE 17 EUROPE: REGULATORY PROCESS FOR IVD DEVICES
                    5.3.1.4 Japan
                                FIGURE 18 REGULATORY PROCESS FOR IVD DEVICES IN JAPAN
                                TABLE 4 JAPAN: CLASSIFICATION OF IVD REAGENTS CLASSIFICATION OF IVD REAGENTS IN JAPAN
                                TABLE 5 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
                    5.3.1.5 China
                                TABLE 6 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
                    5.3.1.6 India
                                FIGURE 19 INDIA: REGULATORY PROCESS FOR IVD DEVICES
                    5.3.1.7 Russia
                                TABLE 7 RUSSIA: CLASSIFICATION OF IVD DEVICES
                    5.3.1.8 Mexico
                                FIGURE 20 MEXICO: REGULATORY PROCESS FOR IVD DEVICES
                                TABLE 8 MEXICO: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
                    5.3.1.9 Brazil
                                FIGURE 21 BRAZIL: REGULATORY PROCESS FOR IVD DEVICES
                    5.3.1.10 South Korea
                                 TABLE 9 SOUTH KOREA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
    5.4 REIMBURSEMENT SCENARIO
          TABLE 10 REIMBURSEMENT CODES FOR VARIOUS BIOMARKERS
    5.5 VALUE CHAIN ANALYSIS
          FIGURE 22 CARDIAC MARKER TESTING MARKET: VALUE CHAIN ANALYSIS
    5.6 SUPPLY CHAIN ANALYSIS
          FIGURE 23 DIRECT DISTRIBUTION—PREFERRED STRATEGY FOR PROMINENT COMPANIES
    5.7 ECOSYSTEM ANALYSIS: PARENT MARKET (IN VITRO DIAGNOSTICS)
    5.8 PRICING ANALYSIS
           5.8.1 AVERAGE SELLING PRICE OF CARDIAC MARKET TEST KITS BY KEY PLAYERS
                    TABLE 11 CARDIAC BIOMARKER TROPONIN I AND T TEST KITS
                    TABLE 12 CARDIAC BIOMARKER CK-MB TEST KITS
                    TABLE 13 CARDIAC BIOMARKER BPN OR NT-PROBNP TEST KITS
                    TABLE 14 CARDIAC BIOMARKER MYOGLOBIN TEST KITS
                    TABLE 15 CARDIAC BIOMARKER C-REACTIVE PROTEIN (HS-CRP) TEST KITS
                    TABLE 16 AVERAGE SELLING PRICE OF CARDIAC MARKET TEST KITS TREND, BY COUNTRY (USD)
    5.9 PORTER’S FIVE FORCES ANALYSIS
          TABLE 17 CARDIAC MARKER TESTING MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.9.1 BARGAINING POWER OF BUYERS
           5.9.2 BARGAINING POWER OF SUPPLIERS
           5.9.3 THREAT OF NEW ENTRANTS
           5.9.4 THREAT OF SUBSTITUTES
           5.9.5 INTENSITY OF COMPETITIVE RIVALRY
    5.10 PATENT ANALYSIS
           FIGURE 24 TOP 10 PATENT APPLICANTS FOR CARDIAC MARKER TESTING (JANUARY 2012–SEPTEMBER 2022)
           FIGURE 25 TOP 10 PATENT OWNERS FOR CARDIAC MARKER TESTING (JANUARY 2012–SEPTEMBER 2022)
    5.11 KEY CONFERENCES & EVENTS (2022–2024)
           TABLE 18 CARDIAC MARKER TESTING MARKET: DETAILED LIST OF MAJOR CONFERENCES & EVENTS
    5.12 CASE STUDY
           5.12.1 DEVELOPMENT OF HIGH-SENSITIVITY TROPONIN I
                      TABLE 19 CASE 1: DIAGNOSING LOWER LEVEL OF TROPONIN IN CARDIAC PATIENTS
    5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
    5.14 KEY STAKEHOLDERS & BUYING CRITERIA
           5.14.1 KEY STAKEHOLDERS
                      FIGURE 26 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR CARDIAC MARKER TESTING KITS AND INSTRUMENTS
                      TABLE 20 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR PRODUCT SEGMENTS (%)
    5.15 KEY BUYING CRITERIA BY END USERS
           TABLE 21 KEY BUYING CRITERIA FOR PRODUCTS

6 CARDIAC MARKER TESTING MARKET, BY PRODUCT (Page No. - 72)
    6.1 INTRODUCTION
          TABLE 22 CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
    6.2 REAGENTS & KITS
           6.2.1 RISING VOLUME OF DIAGNOSTIC TESTS TO DRIVE DEMAND
                    TABLE 23 CARDIAC MARKER TESTING MARKET FOR REAGENTS & KITS, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 24 CARDIAC MARKER TESTING MARKET FOR REAGENTS & KITS, BY BIOMARKER TYPE, 2020–2027 (USD MILLION)
    6.3 INSTRUMENTS
                    TABLE 25 CARDIAC MARKER TESTING MARKET FOR INSTRUMENTS, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 26 CARDIAC MARKER TESTING MARKET FOR INSTRUMENTS, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                    TABLE 27 CARDIAC MARKER TESTING MARKET FOR INSTRUMENTS, BY BIOMARKER TYPE, 2020–2027 (USD MILLION)
           6.3.1 CHEMILUMINESCENCE
                    6.3.1.1 Most preferred method for quantification of cardiac biomarkers to drive segment growth
                                TABLE 28 CARDIAC MARKER TESTING MARKET FOR CHEMILUMINESCENCE, BY REGION, 2020–2027 (USD MILLION)
                                TABLE 29 CARDIAC MARKER TESTING MARKET FOR CHEMILUMINESCENCE, BY BIOMARKER TYPE, 2020–2027 (USD MILLION)
           6.3.2 IMMUNOFLUORESCENCE
                    6.3.2.1 Demand for stable and safer reagents to support market growth
                                TABLE 30 CARDIAC MARKER TESTING MARKET FOR IMMUNOFLUORESCENCE, BY REGION, 2020–2027 (USD MILLION)
                                TABLE 31 CARDIAC MARKER TESTING MARKET FOR IMMUNOFLUORESCENCE, BY BIOMARKER TYPE, 2020–2027 (USD MILLION)
           6.3.3 ELISA
                    6.3.3.1 Long shelf life and ease of use to propel segment growth
                                TABLE 32 CARDIAC MARKER TESTING MARKET FOR ELISA, BY REGION, 2020–2027 (USD MILLION)
                                TABLE 33 CARDIAC MARKER TESTING MARKET FOR ELISA, BY BIOMARKER TYPE, 2020–2027 (USD MILLION)
           6.3.4 IMMUNOCHROMATOGRAPHY
                    6.3.4.1 Increasing use in point-of-care settings to drive adoption of this technique
                                TABLE 34 CARDIAC MARKER TESTING MARKET FOR IMMUNOCHROMATOGRAPHY, BY REGION, 2020–2027 (USD MILLION)
                                TABLE 35 CARDIAC MARKER TESTING MARKET FOR IMMUNOCHROMATOGRAPHY, BY BIOMARKER TYPE, 2020–2027 (USD MILLION)

7 CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE (Page No. - 82)
    7.1 INTRODUCTION
          TABLE 36 CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2020–2027 (USD MILLION)
    7.2 TROPONIN I AND T
           7.2.1 HIGH SENSITIVITY AND SPECIFICITY IN DETECTION OF CVD TO DRIVE MARKET
                    TABLE 37 CHARACTERISTICS OF TROPONIN CARDIAC MARKERS
                    TABLE 38 CARDIAC MARKER TESTING MARKET FOR TROPONIN I AND T, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 39 CARDIAC MARKER TESTING MARKET FOR TROPONIN I AND T, BY DISEASE, 2020–2027 (USD MILLION)
                    TABLE 40 CARDIAC MARKER TESTING MARKET FOR TROPONIN I AND T, BY END USER, 2020–2027 (USD MILLION)
    7.3 CREATINE KINASE-MB (CK-MB)
           7.3.1 DIAGNOSIS OF ACUTE MYOCARDIAL INJURY USING CK-MB TO DRIVE MARKET
                    TABLE 41 CHARACTERISTICS OF CK-MB CARDIAC MARKER
                    TABLE 42 CARDIAC MARKER TESTING MARKET FOR CREATINE KINASE-MB (CK-MB), BY REGION, 2020–2027 (USD MILLION)
                    TABLE 43 CARDIAC MARKER TESTING MARKET FOR CREATINE KINASE-MB (CK-MB), BY DISEASE, 2020–2027 (USD MILLION)
                    TABLE 44 CARDIAC MARKER TESTING MARKET FOR CREATINE KINASE-MB (CK-MB), BY END USER, 2020–2027 (USD MILLION)
    7.4 NATRIURETIC PEPTIDE (BNP AND NT-PROBNP)
           7.4.1 USE OF BNP WITH OTHER CARDIAC MARKERS TO ENHANCE UTILIZATION
                    TABLE 45 CARDIAC MARKER TESTING MARKET FOR NATRIURETIC PEPTIDE (BNP AND NT-PROBNP), BY REGION, 2020–2027 (USD MILLION)
                    TABLE 46 CARDIAC MARKER TESTING MARKET FOR NATRIURETIC PEPTIDE (BNP AND NT-PROBNP), BY DISEASE, 2020–2027 (USD MILLION)
                    TABLE 47 CARDIAC MARKER TESTING MARKET FOR NATRIURETIC PEPTIDE (BNP AND NT-PROBNP), BY END USER, 2020–2027 (USD MILLION)
    7.5 MYOGLOBIN
           7.5.1 RAPID INCREASE AND NORMALIZATION ASSOCIATED WITH MYOGLOBIN TO DRIVE MARKET
                    TABLE 48 CHARACTERISTICS OF MYOGLOBIN CARDIAC MARKERS
                    TABLE 49 CARDIAC MARKER TESTING MARKET FOR MYOGLOBIN, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 50 CARDIAC MARKER TESTING MARKET FOR MYOGLOBIN, BY DISEASE, 2020–2027 (USD MILLION)
                    TABLE 51 CARDIAC MARKER TESTING MARKET FOR MYOGLOBIN, BY END USER, 2020–2027 (USD MILLION)
    7.6 HIGH-SENSITIVITY C-REACTIVE PROTEIN (HSCRP)
           7.6.1 ABILITY OF HSCRP TESTS TO ACCURATELY MEASURE LOW LEVELS OF CRP TO SUPPORT MARKET GROWTH
                    TABLE 52 CUT-OFFS FOR CRP USING STANDARDIZED ASSAYS
                    TABLE 53 CARDIAC MARKER TESTING MARKET FOR HIGH-SENSITIVITY C-REACTIVE PROTEIN (HSCRP), BY REGION, 2020–2027 (USD MILLION)
                    TABLE 54 CARDIAC MARKER TESTING MARKET FOR HIGH-SENSITIVITY C-REACTIVE PROTEIN (HSCRP), BY DISEASE, 2020–2027 (USD MILLION)
                    TABLE 55 CARDIAC MARKER TESTING MARKET FOR HIGH-SENSITIVITY C-REACTIVE PROTEIN (HSCRP), BY END USER, 2020–2027 (USD MILLION)
    7.7 OTHER CARDIAC BIOMARKERS
          TABLE 56 CARDIAC MARKER TESTING MARKET FOR OTHER CARDIAC BIOMARKERS, BY REGION, 2020–2027 (USD MILLION)
          TABLE 57 CARDIAC MARKER TESTING MARKET FOR OTHER CARDIAC BIOMARKERS, BY DISEASE, 2020–2027 (USD MILLION)
          TABLE 58 CARDIAC MARKER TESTING MARKET FOR OTHER CARDIAC BIOMARKERS, BY END USER, 2020–2027 (USD MILLION)

8 CARDIAC MARKER TESTING MARKET, BY DISEASE (Page No. - 96)
    8.1 INTRODUCTION
          TABLE 59 CARDIAC MARKER TESTING MARKET, BY DISEASE, 2020–2027 (USD MILLION)
    8.2 MYOCARDIAL INFARCTION
           8.2.1 AVAILABILITY OF HIGH-SENSITIVITY BIOMARKERS FOR DETECTION OF MI TO DRIVE MARKET
                    TABLE 60 CARDIAC MARKER TESTING MARKET FOR MYOCARDIAL INFARCTION, BY REGION, 2020–2027 (USD MILLION)
    8.3 CONGESTIVE HEART FAILURE
           8.3.1 INCREASING USE OF MULTI-MARKER TESTING TO SUPPORT MARKET GROWTH
                    TABLE 61 CARDIAC MARKER TESTING MARKET FOR CONGESTIVE HEART FAILURE, BY REGION, 2020–2027 (USD MILLION)
    8.4 ACUTE CORONARY SYNDROME
           8.4.1 INCREASING INCIDENCE OF RISK FACTORS ASSOCIATED WITH ACS TO DRIVE ADOPTION OF CARDIAC MARKERS
                    TABLE 62 CARDIAC MARKER TESTING MARKET FOR ACUTE CORONARY SYNDROME, BY REGION, 2020–2027 (USD MILLION)
    8.5 ATHEROSCLEROSIS
           8.5.1 HIGH PREVALENCE OF ATHEROSCLEROSIS TO DRIVE UPTAKE OF CARDIAC MARKERS
                    TABLE 63 CARDIAC MARKER TESTING MARKET FOR ATHEROSCLEROSIS, BY REGION, 2020–2027 (USD MILLION)
    8.6 ISCHEMIA
           8.6.1 MULTIPLE COMPLICATIONS CAUSED BY ISCHEMIA TO DRIVE ADOPTION OF DIAGNOSTIC TESTS
                    TABLE 64 CARDIAC MARKER TESTING MARKET FOR ISCHEMIA, BY REGION, 2020–2027 (USD MILLION)

9 CARDIAC MARKER TESTING MARKET, BY END USER (Page No. - 102)
    9.1 INTRODUCTION
                    TABLE 65 CARDIAC MARKER TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)
    9.2 LABORATORY TESTING FACILITIES
          TABLE 66 CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY TYPE, 2020–2027 (USD MILLION)
          TABLE 67 CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY REGION, 2020–2027 (USD MILLION)
           9.2.1 HOSPITAL LABORATORIES
                    9.2.1.1 Emergency patient care and early diagnosis associated with in-house labs to drive market
                                TABLE 68 CARDIAC MARKER TESTING MARKET FOR HOSPITAL LABORATORIES, BY REGION, 2020–2027 (USD MILLION)
           9.2.2 REFERENCE LABORATORIES
                    9.2.2.1 Affordable and time-efficient services associated with reference laboratories to support market growth
                                TABLE 69 CARDIAC MARKER TESTING MARKET FOR REFERENCE LABORATORIES, BY REGION, 2020–2027 (USD MILLION)
           9.2.3 CONTRACT TESTING LABORATORIES
                    9.2.3.1 Ability to perform multiple tests and cover wider matrices to support market growth
                              TABLE 70 CARDIAC MARKER TESTING MARKET FOR CONTRACT TESTING LABORATORIES, BY REGION, 2020–2027 (USD MILLION)
    9.3 ACADEMIC INSTITUTES
           9.3.1 CONTINUOUS RESEARCH & DEVELOPMENT OF NOVEL BIOMARKERS TO DRIVE MARKET
                    TABLE 71 CARDIAC MARKER TESTING MARKET FOR ACADEMIC INSTITUTES, BY REGION, 2020–2027 (USD MILLION)
    9.4 POINT-OF-CARE TESTING FACILITIES
           9.4.1 EARLY DETECTION AND LOWER TURNAROUND TIME TO DRIVE MARKET
                    TABLE 72 CARDIAC MARKER TESTING MARKET FOR POINT-OF-CARE TESTING FACILITIES, BY REGION, 2020–2027 (USD MILLION)

10 CARDIAC MARKER TESTING MARKET, BY REGION (Page No. - 109)
     10.1 INTRODUCTION
                      TABLE 73 CARDIAC MARKER TESTING MARKET, BY REGION, 2020–2027 (USD MILLION)
     10.2 NORTH AMERICA
             FIGURE 27 NORTH AMERICA: CARDIAC MARKER TESTING MARKET SNAPSHOT
             TABLE 74 NORTH AMERICA: CARDIAC MARKER TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
             TABLE 75 NORTH AMERICA: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2020–2027 (USD MILLION)
             TABLE 76 NORTH AMERICA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
             TABLE 77 NORTH AMERICA: CARDIAC MARKER TESTING INSTRUMENTS, BY TECHNOLOGY, 2020–2027 (USD MILLION)
             TABLE 78 NORTH AMERICA: CARDIAC MARKER TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)
             10.2.1 US
                        10.2.1.1 Growing support from NIH for development of novel cardiac biomarkers to drive market
                                      TABLE 79 US: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
             10.2.2 CANADA
                        10.2.2.1 Increasing government initiatives supporting cardiac marker testing to boost market growth
                                      TABLE 80 CANADA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
     10.3 EUROPE
             TABLE 81 EUROPE: CARDIAC MARKER TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
             TABLE 82 EUROPE CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2020–2027 (USD MILLION)
             TABLE 83 EUROPE: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
             TABLE 84 EUROPE: CARDIAC MARKER TESTING MARKET FOR INSTRUMENTS, BY TECHNOLOGY, 2020–2027 (USD MILLION)
             TABLE 85 EUROPE: CARDIAC MARKER TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)
             10.3.1 GERMANY
                        10.3.1.1 Higher healthcare expenditure to drive demand for diagnostic tests
                                     TABLE 86 GERMANY: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
             10.3.2 UK
                        10.3.2.1 Government initiatives to expand diagnostic facilities to boost adoption of cardiac biomarkers
                                     TABLE 87 UK: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
             10.3.3 FRANCE
                        10.3.3.1 Rising demand for early CVD diagnosis to drive market
                                     TABLE 88 FRANCE: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
             10.3.4 ITALY
                        10.3.4.1 Adoption of advanced diagnostic technologies to drive market
                                     TABLE 89 ITALY: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
             10.3.5 SPAIN
                        10.3.5.1 Establishment of large and advanced laboratories to drive uptake of cardiac marker testing
                                     TABLE 90 SPAIN: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
             10.3.6 REST OF EUROPE (ROE)
                       TABLE 91 REST OF EUROPE: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
     10.4 ASIA PACIFIC
             FIGURE 28 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET SNAPSHOT
             TABLE 92 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
             TABLE 93 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2020–2027 (USD MILLION)
             TABLE 94 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
             TABLE 95 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR INSTRUMENTS, BY TECHNOLOGY, 2020–2027 (USD MILLION)
             TABLE 96 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)
             10.4.1 JAPAN
                        10.4.1.1 Presence of established healthcare system with advanced laboratory facilities to drive market
                                     TABLE 97 JAPAN: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
             10.4.2 CHINA
                        10.4.2.1 Increasing number of independent clinical laboratories to drive demand for cardiac markers
                                     TABLE 98 CHINA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
             10.4.3 INDIA
                        10.4.3.1 Presence of large patient population to drive demand for cardiac marker testing
                                     TABLE 99 INDIA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
             10.4.4 SOUTH KOREA
                        10.4.4.1 Growing number of private hospitals to drive adoption of advanced testing services
                                     TABLE 100 SOUTH KOREA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
             10.4.5 AUSTRALIA
                        10.4.5.1 High healthcare expenditure to support market growth
                                     TABLE 101 AUSTRALIA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
             10.4.6 REST OF ASIA PACIFIC (ROAPAC)
                       TABLE 102 REST OF ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
     10.5 LATIN AMERICA
             TABLE 103 LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
             TABLE 104 LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2020–2027 (USD MILLION)
             TABLE 105 LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
             TABLE 106 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR INSTRUMENTS, BY TECHNOLOGY, 2020–2027 (USD MILLION)
             TABLE 107 LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)
             10.5.1 BRAZIL
                        10.5.1.1 Rising government support for advancements in healthcare to support market growth
                                     TABLE 108 BRAZIL: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
             10.5.2 MEXICO
                        10.5.2.1 Rising demand for technologically advanced products to drive uptake for cardiac markers
                                     TABLE 109 MEXICO: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
             10.5.3 REST OF LATIN AMERICA (ROLATAM)
                       TABLE 110 REST OF LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
     10.6 MIDDLE EAST & AFRICA
             10.6.1 RISING IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE TO DRIVE DEMAND FOR ADVANCED MARKERS
                        TABLE 111 MIDDLE EAST & AFRICA: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2020–2027 (USD MILLION)
                        TABLE 112 MIDDLE EAST & AFRICA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                        TABLE 113 MIDDLE EAST & AFRICA: CARDIAC MARKER TESTING MARKET FOR INSTRUMENTS, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                        TABLE 114 MIDDLE EAST & AFRICA: CARDIAC MARKER TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)

11 COMPETITIVE LANDSCAPE (Page No. - 135)
     11.1 OVERVIEW
     11.2 STRATEGIES ADOPTED BY KEY PLAYERS/RIGHT TO WIN
             FIGURE 29 OVERVIEW OF STRATEGIES ADOPTED BY COMPANIES (2019−2022)
     11.3 REVENUE ANALYSIS
             FIGURE 30 REVENUE SHARE ANALYSIS OF TOP FIVE PLAYERS (2018−2021)
     11.4 CARDIAC MARKER TESTING MARKET: MARKET SHARE ANALYSIS, BY KEY PLAYER (2021)
             FIGURE 31 CARDIAC MARKER TESTING MARKET SHARE, BY KEY PLAYER (2021)
             TABLE 115 CARDIAC MARKER TESTING MARKET: DEGREE OF COMPETITION
     11.5 COMPANY EVALUATION QUADRANT FOR MAJOR PLAYERS (AS OF 2021)
             11.5.1 STARS
             11.5.2 EMERGING LEADERS
             11.5.3 PERVASIVE PLAYERS
             11.5.4 PARTICIPANTS
                        FIGURE 32 CARDIAC MARKER TESTING MARKET: COMPANY EVALUATION QUADRANT (2021)
     11.6 COMPANY EVALUATION QUADRANT (SMES/STARTUPS)
             11.6.1 PROGRESSIVE COMPANIES
             11.6.2 RESPONSIVE COMPANIES
             11.6.3 DYNAMIC COMPANIES
             11.6.4 STARTING BLOCKS
                        FIGURE 33 CARDIAC MARKER TESTING MARKET:COMPETITIVE LEADERSHIP MAPPING (SMES/STARTUPS)
     11.7 COMPETITIVE BENCHMARKING
             TABLE 116 OVERALL FOOTPRINT ANALYSIS
             TABLE 117 PRODUCT FOOTPRINT ANALYSIS
             TABLE 118 REGIONAL FOOTPRINT ANALYSIS
     11.8 COMPETITIVE SCENARIO (2019–2022)
             11.8.1 PRODUCT LAUNCHES & APPROVALS
             11.8.2 DEALS
             11.8.3 OTHER DEVELOPMENTS

12 COMPANY PROFILES (Page No. - 148)
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
     12.1 KEY PLAYERS
             12.1.1 F. HOFFMANN-LA ROCHE AG
                        TABLE 119 F. HOFFMANN-LA ROCHE AG: BUSINESS OVERVIEW
                        FIGURE 34 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2021)
             12.1.2 ABBOTT LABORATORIES
                        TABLE 120 ABBOTT LABORATORIES: BUSINESS OVERVIEW
                        FIGURE 35 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2021)
             12.1.3 SIEMENS HEALTHINEERS AG
                        TABLE 121 SIEMENS HEALTHINEERS AG: BUSINESS OVERVIEW
                        FIGURE 36 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2021)
             12.1.4 DANAHER CORPORATION
                        TABLE 122 DANAHER CORPORATION: BUSINESS OVERVIEW
                        FIGURE 37 DANAHER CORPORATION: COMPANY SNAPSHOT (2021)
             12.1.5 BIOMÉRIEUX SA
                        TABLE 123 BIOMÉRIEUX SA: BUSINESS OVERVIEW
                        FIGURE 38 BIOMÉRIEUX SA: COMPANY SNAPSHOT (2021)
             12.1.6 BECTON, DICKINSON AND COMPANY (BD)
                        TABLE 124 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
                        FIGURE 39 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2021)
             12.1.7 BIO-RAD LABORATORIES, INC.
                        TABLE 125 BIO-RAD LABORATORIES, INC: BUSINESS OVERVIEW
                        FIGURE 40 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2021)
             12.1.8 THERMO FISHER SCIENTIFIC INC.
                        TABLE 126 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW
                        FIGURE 41 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2021)
             12.1.9 DIASORIN
                        TABLE 127 DIASORIN: BUSINESS OVERVIEW
                        FIGURE 42 DIASORIN: COMPANY SNAPSHOT (2021)
             12.1.10 PERKINELMER, INC.
                        TABLE 128 PERKINELMER INC: BUSINESS OVERVIEW
                        FIGURE 43 PERKINELMER INC: COMPANY SNAPSHOT (2021)
             12.1.11 TOSOH CORPORATION
                        TABLE 129 TOSOH CORPORATION: BUSINESS OVERVIEW
                        FIGURE 44 TOSOH CORPORATION: COMPANY SNAPSHOT (2022)
             12.1.12 LSI MEDIENCE CORPORATION (PHC HOLDINGS CORPORATION)
                        TABLE 130 LSI MEDIENCE CORPORATION: BUSINESS OVERVIEW
                        FIGURE 45 PHC HOLDINGS CORPORATION: COMPANY SNAPSHOT (2021)
             12.1.13 QUIDEL CORPORATION
                        TABLE 131 QUIDEL CORPORATION: BUSINESS OVERVIEW
                        FIGURE 46 QUIDEL CORPORATION: COMPANY SNAPSHOT (2021)
             12.1.14 RANDOX LABORATORIES
                        TABLE 132 RANDOX LABORATORIES: BUSINESS OVERVIEW
             12.1.15 GUANGZHOU WONDFO BIOTECH CO., LTD.
                        TABLE 133 GUANGZHOU WONDFO BIOTECH CO., LTD.: BUSINESS OVERVIEW
             12.1.16 BODITECH MED INC.
                        TABLE 134 BODITECH MED INC: BUSINESS OVERVIEW
             12.1.17 TULIP (P) DIAGNOSTICS LTD
                        TABLE 135 TULIP (P) DIAGNOSTICS LTD: BUSINESS OVERVIEW
             12.1.18 BTNX INC.
                        TABLE 136 BTNX INC.: BUSINESS OVERVIEW
             12.1.19 RESPONSE BIOMEDICAL
                        TABLE 137 RESPONSE BIOMEDICAL: BUSINESS OVERVIEW
             12.1.20 ALFA SCIENTIFIC DESIGNS, INC.
                        TABLE 138 ALFA SCIENTIFIC DESIGNS, INC: BUSINESS OVERVIEW
     12.2 OTHER PLAYERS
             12.2.1 CTK BIOTECH, INC.
             12.2.2 CREATIVE DIAGNOSTICS
             12.2.3 LIFESIGN LLC.
             12.2.4 CARDIOGENICS HOLDINGS INC
             12.2.5 ATLAS MEDICAL GMBH

*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

13 APPENDIX (Page No. - 202)
     13.1 DISCUSSION GUIDE
     13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     13.3 CUSTOMIZATION OPTIONS
     13.4 RELATED REPORTS
     13.5 AUTHOR DETAILS

The study involved four major activities to estimate the current size of the cardiac marker testing market. Exhaustive secondary research was carried out to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Top-down and bottom-up approaches were employed to estimate the complete market size. Thereafter, market breakdown and data triangulation procedures were used to estimate the size of segments and subsegments.

Secondary Research

The secondary sources referred to in this research study include corporate filings (such as annual reports, SEC filings, investor presentations, and financial statements); research journals; and press releases; trade, business, and professional associations. Secondary sources were used to identify and collect useful information for this extensive and commercial study of the cardiac marker testing market. Secondary research was mainly used to obtain key information about the industry’s total pool of key players, market classification and segmentation according to industry trends to the bottom-most level, market trends, and critical developments by both the public and private organizations in the cardiac marker testing market.

The secondary sources referred to for this research study include government sources, independent or public sources, paid/private databases, and research databases, among others. Secondary data was collected and analyzed to arrive at the overall market size of the cardiac marker testing market, which was further validated by primary research. Some of the key secondary sources referred to during the preparation of this report are listed below-

  • Governmental and inter-governmental sources & databases such as World Health Organization (WHO), World Bank, Organisation for Economic Co-operation and Development (OECD), and Centers for Disease Control and Prevention (CDC), among others.
  • Business and research articles such as Springer Nature, The Lancet, PubMed, and US National Library of Medicine, among others.
  • Company sources involving annual reports, SEC filings, regulatory filings, investor presentations, press releases, and financial statements, among others.

Primary Research

Extensive primary research was conducted after acquiring knowledge about the cardiac marker testing market scenario through secondary research. A significant number of primary interviews were conducted from both the demand (healthcare providers, research and academic institutes, hospitals laboratories, point-of-care testing facilities) and supply sides (developers, manufacturers, and distributors of cardiac marker testing products). The primaries interviewed for this study include experts from the in vitro diagnostics (IVD) industry  (such as CEOs, VPs, directors, sales heads, and marketing managers of tier 1, 2, and 3 companies engaged in offering cardiac biomarker test kits and instruments across the globe) and administrators & purchase managers of hospitals and diagnostic centers.

Around 65% and 35% of primary interviews were conducted from the supply and demand side, respectively. A robust primary research methodology has been adopted to validate the contents of the report and to fill gaps. Telephonic and e-mail communications were adopted to conduct interviews (questionnaires were designed and sent to primary participants as per their convenience).

Primary Research

The cardiac marker testing market comprises several stakeholders, such as diagnostic laboratories, clinical testing facilities, research laboratories and academic institutions, and point-of-care testing laboratories. The demand side of this market is characterized growing incidence of cardiovascular diseases, rapidly increasing geriatric population, growing funding from public and private organizations for research on cardiac biomarkers, and ongoing clinical trials for the identification of novel cardiac biomarkers. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is the breakdown of primary respondents:

Cardiac Marker Testing Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the cardiac marker testing market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry and markets have been identified through extensive secondary research
  • The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

Cardiac Marker Testing Market Estimation

To know about the assumptions considered for the study, Request for Free Sample Report

Data Triangulation

After arriving at the overall market size—using the market size estimation processes as explained above—the cardiac marker testing market was split into several segments and subsegments. In order to complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the cardiac marker testing industry.

Report Objectives

  • To define, describe, and forecast the cardiac marker testing market by product, biomarker type, disease, end user, and region
  • To provide detailed information about major factors influencing market growth (key drivers, restraints, opportunities, and industry-specific challenges)
  • To strategically analyze micromarkets1 with respect to individual growth trends, prospects, and their contributions to the overall cardiac marker testing market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the market value of various segments and sub-segments with respect to five main regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
  • To profile the key players active in the cardiac marker testing market and comprehensively analyze their global revenue shares and core competencies2
  • To track and analyze competitive market-specific developments such as product approvals & commercialization, agreements, partnerships, collaborations, acquisitions, and expansions in the cardiac marker testing market

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the cardiac marker testing market report:

Product Analysis

  • Product Matrix, which gives a detailed comparison of the product portfolios of the top five global players

Product Analysis

  • Further breakdown of the Rest of Europe cardiac marker testing  market into Russia, Portugal, Belgium, Denmark, and Switzerland, and other European countries (aggregated)

Company Information

  • Detailed analysis and profiling of additional market players (up to 5 OEMs)
Report Code
MD 4673
Published ON
Oct, 2022
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Cardiac Marker Testing Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2023 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback